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Abstract Phosphofructokinase (PFK) subunits and isozymes 
have been examined in ascites tumor cells and murine mammary 
gland, the tissue from where this tumor originated. Ascites tumor 
was found to contain predominantly the C-type subunit, whereas 
the L-type subunit was more abundant in mammary gland. An 
altered M-type subunit of lower electrophoretic mobility was 
found in both cell types and no M4 homotetramers were detected 
in either of them. Characteristic regulatory properties of ascites 
tumor PFK, i.e. insensitivity to fructose-l,6-P2 activation and 
inhibition by P-enolpyruvate, were also observed in the mammary 
gland isozyme. The nature of these properties and the contribu-
tion of the distinct subunit types to fructose-l,6-P2 activation are 
discussed. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Phosphofructokinase (PFK) from mammalian cells is 
known to be composed of three types of subunits (C, M 
and L) that have different electrophoretic mobility and form 
homo- and hetero-oligomers [1-4]. This gives rise to a series of 
isozymes which smallest active species are tetramers. Each 
subunit is encoded by different genes that exhibit tissue-spe-
cific expression. Thus, adult muscle contains only the M-type 
subunit, liver mainly contains the L-type subunit and all three 
types are present in brain [1,2]. The general pattern of PFK as 
a highly modulated allosteric enzyme whose activity is con-
trolled by a number of effectors [5] is common to the various 
isozymes. However, the subunit composition has been shown 
[2,6-10] to promote kinetic and regulatory differences, mostly 
quantitative, among the isozyme pools that affect to the affin-
ity for fructose-6-P and for some of the effectors, such as 
ATP, AMP or fructose-2,6-P2, and that were suggested 
[2,6,8,9] to contribute to the characteristics of the glycolytic 
operation in particular tissues. 
In ascites tumor cells, PFK activity has been demonstrated 
[11] to strongly limit the glycolytic flux under certain condi-
tions and some individual regulatory properties, such as a lack 
of activation by fructose-1,6-P2, were reported [12] for this 
enzyme. PFK isozymes have been investigated in tumor cells 
[3,13-16], but no determinations of their subunit distribution 
were described. In the present work, we have analyzed the 
subunit composition and isozymes of ascites tumor PFK by 
electrophoretic, immunological and Chromatographie techni-
ques to gain some insight into the bases of its peculiar regu-
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latory behavior. As the Erlich-Lettré strain of ascites tumor 
was obtained from a transplantable mouse carcinoma of 
mammary origin [17,18], we have also examined in a compar-
ative way the subunits and properties of the enzyme from 
murine mammary gland to investigate whether the particular 
characteristics of PFK from ascites tumor are related to the 
malignant nature of these cells. 
2. Materials and methods 
2.1. Materials 
Biochemicals were purchased from Boehringer-Mannheim or Sig-
ma. Auxiliary enzymes, blue Sepharose CL-6B and protein-A-Sephar-
ose CL-4B were obtained from Sigma. DEAE-trisacryl M was from 
Biotechnics. Goat anti-(rabbit immunoglobulin G)-peroxidase conju-
gate was from Nordic. Antibodies against the M and L subunits of 
rat muscle and liver PFK, respectively, and against brain PFK 
were kindly donated by Dr. G.A. Dunaway (Southern Illinois Univer-
sity). 
2.2. Cells and tissues 
A hypertriploid strain of Ehrlich-Lettré ascites carcinoma cells was 
grown in the abdominal cavity of 2-month-old male Swiss mice. Cells 
were harvested and washed as described previously [12]. Muscle and 
liver were obtained from male Swiss mice. Brain was obtained from 
male Sprague-Dawley rats. Mammary gland tissue was obtained from 
lactating Swiss mice on day 8-10 of lactation. 
2.3. Preparation of extracts 
Fresh cells and tissues were washed in 115 mM NaCl, 5 mM po-
tassium phosphate, pH 7.4, and suspended in 2-3 vol. extraction 
buffer as described below. Ascites cells were frozen and thawed twice 
in liquid nitrogen. Tissues were homogenized in a Polytron. The ho-
mogenates were centrifuged at 9000 X g for 10 min at 4°C and then at 
105 000 X g for 30 min. The supernatant fluids were collected. 
2.4. Analysis of PFK isozymes 
PFK isozymes were analyzed by SDS-PAGE, Western blotting and 
immunotitration with specific antibodies and ion exchange chroma-
tography (DEAE-trisacryl). 
For SDS-PAGE, Western blotting and immunotitration, extracts in 
buffer A (50 mM Tris-phosphate, 0.05 mM fructose-1,6-P2, 0.1 mM 
EDTA, 1 mM DTT, 50 mM NaF, 0.5 mM phenylmethylsulfonyl 
fluoride, pH 8.0) were chromatographed on a column (1x5 cm) of 
blue Sepharose CL-6B equilibrated with buffer A. The column was 
washed with 50 ml of buffer A and then with the same buffer con-
taining 0.15 mM ADP. PFK activity was eluted with buffer A con-
taining 2 mM fructose-6-P and 2 mM ATP. Fractions of 2 ml were 
collected and those showing PFK activity were pooled. Complete 
recovery of activity was obtained. The pooled fractions were subjected 
to SDS-PAGE employing 6% polyacrylamide gels (17X22 cm) ac-
cording to Laemmli [19]. The gels were stained with silver [20]. The 
percentage of each subunit was determined from silver-stained gels as 
relative to the band intensities quantified with a color image scanner 
(Seiko Epson G520A). The apparent Mr values of each subunit were 
determined by using the standards human plasma ci2-macroglobulin 
(180000), Escherichia coli ß-galactosidase (116000), rabbit muscle 
phosphofructokinase (84 000), chicken muscle pyruvate kinase 
(58 000) and porcine heart fumarase (48 500). Transfer of the gel pro-
teins to nitrocellulose paper and Western analysis of PFK subunits 
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with each type of antibody were performed as described previously 
[21], except that the antibody was diluted 1:400. Immunotitrations of 
the pooled blue-Sepharose fractions with PFK antibodies were con-
ducted as previously outlined [21], except that anti-IgG was mixed 
with partially purified PFK in the proportion 3:1. 
Chromatographie analysis of PFK isozymes was carried out essen-
tially as described by Etiemble et al. [22]. Extracts in buffer B (20 mM 
Tris-phosphate, 10 mM ammonium sulfate, 10 mM NaF, 10 mM 2-
mercaptoethanol, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 
2.5 ug/ml leupeptin, 0.01 mM fructose-1,6-P2, 0.2 mM ATP, pH 7.5) 
were applied to a column (1.9X7.8 cm) of DEAE-trisacryl equili-
brated with the same buffer and 3-ml fractions were collected. PFK 
activity was eluted with a linear gradient of buffer B and the same one 
supplemented with 90 mM ammonium sulfate, 73.5 mM potassium 
phosphate and 50 mM NaCl. 
2.5. Assay for PFK 
Unless otherwise stated, the assay mixture contained 50 mM 
HEPES, 100 mM KC1, 5 mM MgCl2, pH 7.2, 0.15 mM NADH, 
5 mM Pi, 1 mM NH4+, 0.1 mM cAMP, 1 mM MgATP, 1.2 U 
aldolase, 10 U triosephosphate isomerase, 1 U glycerophosphate de-
hydrogenase and 5-10 ul of enzyme preparation in a total volume of 
1 ml. After 5 min, the reaction was started by adding 1 mM fructose-
6-P and was followed by measuring the absorbance change at 340 nm 
in a Perkin Elmer Lambda 5 spectrophotometer at 25°C. Glucose-6-P 
was always added to fructose-6-P in a proportion of 3:1. When PFK 
activity was measured under near Fmax conditions, the assay was 
carried out at 0.5 mM MgATP, 5 mM fructose-6-P, pH 8.5. When 
the effects of fructose- 1,6-P2 and fructose-2,6-P2 were examined, pyr-
uvate kinase (1 U) and lactate dehydrogenase (1 U) were used as 
coupling enzymes in the presence of 0.12 mM P-enolpyruvate and 
the absence of Pi, NFLi+ and cAMP; to minimize the inhibitory effect 
of P-enolpyruvate on PFK activity [12], its concentration in this assay 
was about 7 times lower than the obtained K\ value of 0.83 mM (see 
below). Auxiliary enzymes were desalted by centrifugation and dialy-
sis against 10 mM HEPES, pH 7.0, 20% (v/v) glycerol. One unit (U) 
of activity is defined as the amount that catalyzes the conversion of 
1 umol substrate/min under these conditions. Protein was determined 
by the method of Bradford [23] with bovine y-globulin as standard. 
3. Results and discussion 
3.1. Subunit composition and PFK isozymes 
Ascites tumor cells exhibit a high PFK activity, which was 
found to be close to that measured in mouse muscle and rat 
brain and greater than that in mouse liver (18.6 ±1.2, 
27.0 ± 2.4, 12.3 ± 1.8 and 2.4 ±0.15 U/g wet mass, respectively) 
when assayed in cell extracts under near Kmax conditions. This 
agrees with the enhanced glycolytic activity reported in these 
[11] and other proliferating cells [24]. Analysis by SDS-PAGE 
and Western blotting with antibodies against L- and M-type 
subunits and against rat brain PFK, and subunit quantifica-
tion from silver-stained gels (Fig. 1A), indicated that ascites 
tumor contains subunit types C (50%) and L (32%), with Mr 
values of 87 500 ±600 and 78 700 ±1000, respectively, as well 
as a lesser amount (18%o) of an altered M-type subunit of 
lower electrophoretic mobility (Mr = 86 200 ± 600) than the 
M-type subunit of muscle (Mr — 84 000), that partially over-
lapped with the band of the C-type subunit and which we 
called M*-type. A similar difference between the A/r values 
of the subunit types M and M* was observed when ascites 
tumor PFK was compared with the isozyme from brain, 
where 49% of the subunits are M-type [1] (data not shown). 
Ascites tumor cells are therefore among those with the highest 
expression of the C-type subunit, such as rat intestinal muco-
sa, testis and spleen [1] and human fibroblasts [2]. An increase 
in C-rich isozymes was also reported in several malignant 
tissues [3,16], thus it appears that a high expression of this 
subunit type could be usual in tumor cells. The lower content 
of the M*-type subunit detected in ascites tumor was con-
firmed by immunotitration of the PFK activity, as increasing 
amounts of the antibody against the M-type subunit immu-
Fig. 1. Silver stain and Western blot analysis of PFK subunits in ascites tumor cells (A) and murine mammary gland (B). PFK isozymes were 
partially purified from each tissue by blue-Sepharose chromatography an subjected to SDS-PAGE as described under Section 2. Western blots 
were probed with antibodies as indicated. B: Samples from muscle and ascites tumor were also included for comparison with mammary gland; 
peroxidase reaction was allowed to proceed for a longer period of time than in (A) to improve visualization of the M*-type subunit in tumor 
cells. 
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Fig. 2. DEAE-trisacryl chromatography of PFK isozymes from ascites tumor cells and various tissues of the mouse. High-speed supernatants 
were chromatographed on a DEAE-trisacryl column either separately or combined as indicated. Brain tissue was from rats. The method of elu-
tion was as described under Section 2. 
noprecipitated 19% of the enzyme activity from the partially 
purified preparation of enzyme by blue-Sepharose, whereas it 
immunoprecipitated over 90% of the PFK activity in an en-
zyme preparation from skeletal muscle. As shown in Fig. IB, 
the M*-type subunit was also found in murine mammary 
gland. This tissue contained the M*-type subunit in a higher 
proportion (33%) and consisted predominantly of the L-type 
subunit (65%), with only a 2% of the C-type subunit. We do 
not know at present whether the higher Mr value of the M*-
type subunit, as compared to that of the M-type subunit, is 
related to some difference in their coding sequences or to a 
post-translational modification. 
To gain some insight into the association of the different 
subunit types, PFK isozymes in ascites tumor cells as com-
pared to those in muscle, liver, brain and mammary gland 
were analyzed by DEAE-trisacryl chromatography (Fig. 2), 
which was previously used by Etiemble et al. [22] for the 
separation of PFK isozymes in human erythrocytes. Although 
this method did not successfully resolve the various isozymes, 
since tumor PFK activity eluted as a broad heterogeneous 
peak, it clearly indicated that the early eluting homotetramers 
of the M4 type are virtually absent in ascites tumor cells. This 
was best observed when a mixture of muscle (which contains 
only M4 homotetramers [1]) and tumor cell extracts was 
chromatographed. This result agrees with data from Sumi 
and Ui [13] reporting greater affinity of ascites tumor 
PFK for DEAE-Sephadex than the muscle isozyme. As 
expected from the individual Chromatographie profiles, the 
mixture of liver and ascites tumor exhibited an enrichment 
in late eluting species which are probably composed most-
ly of L-type subunits, the predominant subunit type 
in liver [1] and which Etiemble et al. [22] showed to have 
the highest affinity for DEAE-trisacryl. Interestingly, this 
analysis also indicated that M4 homotetramers are prac-
tically absent in liver and mammary gland and are present 
in a very low proportion, if any, in brain, despite that 
this tissue contains a 49% of the M-type subunits [1], thus 
suggesting that as soon as L- or C-type subunits are present, 
the equilibrium of the M-type subunits is shifted to the for-
mation of hybrids and practically no homo-oligomers are 
formed. 
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Fig. 3. Effect of fructose-2,6-P2 and fructose-1,6-P2 on PFK from murine mammary gland and ascites tumor cells. 
3.2. Effect of fructose bisphosphates and P-enolpyruvate on 
PFK isozymes 
Ascites tumor PFK was reported [12] to be insensitive to 
activation by fructose-l,6-P2, whereas greatly activated by 
fructose-2,6-P2, and inhibited by P-enolpyruvate to a higher 
extent than other isozymes. The finding that PFK from mur-
ine mammary gland also contains the M*-type subunit (Fig. 
1), led us to investigate whether this PFK exhibits such pecu-
liar regulatory properties in comparison with the ascites tu-
mor isozyme. As shown in Fig. 3, PFK activity in mammary 
gland was strongly stimulated by fructose-2,6-P2 (A"act = 0.05 
UM), but it was also scarcely activated by fructose-1,6-P2 
when assayed under similar conditions. Although it is difficult 
to extrapolate to the kinetic behavior of the individual sub-
units because of the possible influence of subunit-subunit in-
teractions in the hybrid forms, these results suggest that the 
C-type subunits do not contribute to fructose-1,6-P2 activa-
tion, as this was the predominant subunit type in ascites tu-
mor cells (Fig. 1). In fact, C4 homotetramers (or F4 homote-
tramers, according to the nomenclature of Khan et al. [3]) 
were shown by Meienhofer et al. [6] to be insensitive to acti-
vation by glucose-l,6-P2, which apparently acts similarly to 
fructose-1,6-P2 although with lower affinity [25,26]. Muscle 
PFK (M4 homotetramers) shows the greatest affinity for fruc-
tose-l,6-P2 among PFK isozymes [26,27]. The liver enzyme is 
also activated by fructose-l,6-P2, but only under certain con-
ditions and with a poorer affinity [25]. The fact that mammary 
gland PFK was only slightly activated by fructose-l,6-P2, de-
spite containing as much as a 65% of L-type subunits (Fig. 1), 
may indicate that this subunit type is very little affected by 
fructose-1,6-P2, which main target for PFK activation would 
therefore be the M-type subunit. In addition, the practical 
lack of fructose-1,6-P2 effect on mammary gland PFK also 
suggests that the M*-type subunit is unaffected by this com-
pound, since this isozyme has an amount of the M*-type 
subunit (33%>) even higher than that of ascites tumor PFK 
(19%>), whereas the brain isozyme, which contains a 49% of 
the normal M-type subunit [1], was found to be highly acti-
vated by fructose-1,6-P2 under similar conditions (data not 
shown). Consequently, the insensitivity of ascites tumor 
PFK to fructose-1,6-P2 activation might just reflect its subunit 
composition, i.e. a high proportion of the C-subunit type, a 
relatively lower content of the L-type subunit and the presence 
of the variant M*-type subunit. 
Fig. 4 shows that mammary gland was also inhibited by P-
enolpyruvate, exhibiting an affinity for this compound 
(K[ = 0.83 mM) that practically coincided with that of the 
ascites tumor isozyme. Thus, these data suggest that both 
the presence of the M*-type subunit detected in ascites tumor 
cells and the peculiar kinetic properties initially reported [12] 
for its PFK activity about fructose-1,6-P2 activation and P-
enolpyruvate inhibition, are not related to some malignant 
phenotype of these cells but to the tissue from where the 
tumor proceeds [17,18], whereas the high content of the C-
type subunit is apparently linked to the tumorous character of 
this type of cell. There has been previous studies [3,13-16] on 
the nature of PFK isozymes in cancer cells, and fructose-2,6-
P2 activation of the rat mammary gland isozyme was de-
scribed [28], but to the best of our knowledge this is the first 
determination of the subunit composition of PFK in tumor 
cells and mammary gland and of the effect of fructose-1,6-P2 
and P-enolpyruvate on the enzyme from the latter tissue. 
3.3. Conclusions 
The results presented here show that PFK isozymes in as-
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Fig. 4. Effect of P-enolpyruvate on PFK from murine mammary 
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highest velocity measured with each enzyme. 
90 
cites tumor cells contain mainly C- and L-type subunits and 
to a lesser extent a variant of the M-type subunit of lower 
electrophoretic mobility, referred to as M*-type subunit, 
which was also found in murine mammary gland, the original 
tissue of this tumor [17,18]. The L-type subunit was the more 
abundant subunit type in mammary gland. No M4 homote-
tramers were detected either in ascites tumor or mammary 
gland by column chromatography, this isozyme form being 
also apparently absent in brain and liver. As previously de-
scribed for ascites tumor PFK [12], the mammary gland iso-
zyme was practically insensitive to fructose-1,6-P2 activation 
and equally inhibited by P-enolpyruvate. Our data suggest 
that the altered M*-type subunit is unaffected by fructose-
1,6-P2 and that of the three distinct subunit types of mamma-
lian PFK, the M-type subunit is mainly responsible for acti-
vation by this compound. Additionally, these results indicate 
that the high proportion of the C-type subunit found in as-
cites tumor might be an expression of its malignant nature, 
whereas the presence of the M*-type subunit and the peculiar 
response to fructose bisphosphates and P-enolpyruvate of the 
PFK activity in these cells are related to the tissue from where 
the tumor derived. 
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